Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40073121.
- Also identified by DOI 10.1126/sciadv.adq4416 and PMC identifier 11900870.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Pancreatic cancer (PC) is a highly metastatic malignancy. More than 80% of patients with PC present with advanced-stage disease, preventing potentially curative surgery. The neuropeptide Y (NPY) system, best known for its role in controlling energy homeostasis, has also been shown to promote tumorigenesis in a range of cancer types, but its role in PC has yet to be explored. We show that expression of NPY and <i>NPY1R</i> are up-regulated in mouse PC models and human patients with PC. Moreover, using the genetically engineered, autochthonous KP<sup>R172H</sup>C mouse model of PC, we demonstrate that pancreas-specific and whole-body knockout of <i>Npy1r</i> significantly decreases metastasis to the liver. We identify that treatment with the NPY1R antagonist BIBO3304 significantly reduces KP<sup>R172H</sup>C migratory capacity on cell-derived matrices. Pharmacological NPY1R inhibition in an intrasplenic model of PC metastasis recapitulated the results of our genetic studies, with BIBO3304 significantly decreasing liver metastasis. Together, our results reveal that NPY/NPY1R signaling is a previously unidentified antimetastatic target in PC.
Medical subject headings
- Pancreatic Neoplasms
- Receptors, Neuropeptide Y
- Neuropeptide Y
- Signal Transduction
- Tumor Suppressor Protein p53
- Mutation